Executive Medical Director - Clinical Development, MS and Neuropsychiatry
About the job
- MD with significant clinical experience; clinical training in internal medicine, neurology, or psychiatry is desired.
- At least 10 years of clinical and clinical research experience.
- At least 5 years of management experience and industry experience in late-stage clinical development or medical affairs.
- Demonstrated leadership and team-building skills.
- Strategic and critical thinking for managing assets through their life cycle while considering differing geographic needs.
- Strong oral and written communication skills.
- Strong problem-solving, conflict-resolution, and analytical skills.
- Provide accountability and primary oversight for the execution of multiple portfolio assets.
- Lead activities from a clinical perspective and ensure successful management of development aspects for marketed assets.
- Deliver scientific leadership across trial-level DU activities in partnership with various functions.
- Represent Biogen in external collaborations and events related to these assets, including regulatory discussions and scientific meetings.
- Act as the DU representative in business development activities when required.
- Manage 2-4 programs and focus on meeting post-marketing commitments while liaising with cross-functional partners.
- Collaborate with Regulatory, PDC, Regional, and other core functions across key global regions.
- Contribute to strategy for follow-up activities.
- Clinical training in internal medicine, neurology, or psychiatry.
About the company
Biogen is a global biotechnology company focused on neuroscience. It discovers, develops, and delivers therapies for neurological disorders, such as multiple sclerosis and other neurodegenerative diseases. Its product process starts with research and development to identify potential drugs, followed by clinical testing and regulatory approval, ultimately leading to commercialization and patient treatment. Biogen differentiates itself through a long history (founded in 1978), a deep specialization in neuroscience, and an integrated pipeline that moves ideas from discovery to approved medicines, aiming to create value for shareholders while helping communities. The company’s goal is to advance therapies for neurological diseases to improve patients’ lives and generate sustainable value for stakeholders.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
1978
Get referred to Biogen
See people who can refer or advise you
Simplify's Take
What believers are saying
- LEQEMBI Pen won Japan approval on September 16, 2026, expanding at-home dosing.
- China approved LEQEMBI subcutaneous initiation on September 3, 2026, accelerating access.
- Apellis closed on May 14, 2026, adding SYFOVRE and EMPAVELI revenue.
What critics are saying
- Biogen halted BIIB122 after May 21, 2026 Phase 2b failure in Parkinson’s disease.
- Genentech won $124.3 million against Biogen in November 2025; appeal remains pending.
- TECFIDERA exclusivity expired, generics spread, and 1,400 layoffs expose franchise erosion.
What makes Biogen unique
- Biogen pairs neuroscience depth with marketed Alzheimer’s, MS, and rare-disease franchises.
- Eisai-Biogen launched LEQEMBI IQLIK in the U.S. on August 24, 2026.
- Biogen and Stoke advanced zorevunersen into Phase 3 EMPEROR for Dravet syndrome.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -10%1 year growth
↓ -10%2 year growth
↓ -10%Trigeminal Neuralgia Pipeline Outlook highlights 10+ Companies and 10+ emerging therapies across clinical development stages. September 29 Trigeminal Neuralgia is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock-like or stabbing pain in a region of the face, most frequently affecting the distribution of the second (maxillary) or third (mandibular) division of the trigeminal nerve, with the right side of the face affected more often than the left. (Albany, US) September 28, 2026 - DelveInsight's "Trigeminal Neuralgia - Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Trigeminal Neuralgia pipeline landscape, covering clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, as well as inactive pipeline products. Three types of trigeminal neuralgia have been delineated: classical, secondary, and idiopathic, with bilateral trigeminal neuralgia rare and warranting concern about an underlying neurologic or non-neurologic disorder affecting the cranium. Incidence is higher among women than men and increases with age. Key Takeaways from the Trigeminal Neuralgia Pipeline Report * The Trigeminal Neuralgia pipeline includes 10+ key companies developing therapies, with 10+ products spanning Phase III, Phase II, Phase I, preclinical, and discovery stages, along with discontinued and inactive candidates. * Biogen has the most advanced Trigeminal Neuralgia drug candidate in the pipeline, with Vixotrigine (BIIB074) currently in Phase III development. * Vixotrigine is a centrally and peripherally acting small molecule that functions as a voltage- and use-dependent sodium channel blocker, being developed by Biogen for the treatment of Trigeminal Neuralgia. * Rimegepant, developed by Biohaven Pharmaceuticals, is a calcitonin gene-related peptide (CGRP) receptor antagonist in Phase II development for Trigeminal Neuralgia, with a trial initiated in June 2019. * The pipeline includes therapies across multiple stages of development, highlighting continued innovation in neuropathic pain treatment. * Emerging therapies are being developed through diverse mechanisms, including sodium channel blockers and CGRP receptor antagonists. Gain Strategic Insights into the Trigeminal Neuralgia Pipeline Landscape * Explore the complete Trigeminal Neuralgia Pipeline Outlook. * Analyze Phase III, Phase II, Phase I, preclinical, and discovery-stage assets. * Evaluate emerging companies and late-stage pipeline therapies. * Understand therapeutic assessment by product type, route of administration, and molecule type. * Track collaborations, licensing, acquisitions, and other pipeline development activities. Explore detailed pipeline insights and emerging therapies @ Trigeminal Neuralgia Pipeline Insight Report Trigeminal Neuralgia Disease Overview Pain can be triggered by routine acts, including brushing teeth, shaving, touching the face, eating or drinking, speaking, or a breeze on the face. Diagnosis is clinical, based on pain restricted to the territory of one or more divisions of the trigeminal nerve and sudden, intense, very short paroxysms. The anticonvulsant agents carbamazepine and oxcarbazepine have been considered first-choice treatments for control of paroxysmal pain, with gabapentin, pregabalin, and antidepressant agents tried as additional agents. Microvascular decompression is favored as the surgical procedure for cases not responding to medication. Trigeminal Neuralgia Emerging Drugs Analysis The Trigeminal Neuralgia pipeline features multiple emerging therapies targeting neuropathic pain through novel mechanisms and differentiated therapeutic approaches. Phase III Therapy * Vixotrigine (BIIB074): Biogen - A centrally and peripherally acting small molecule voltage- and use-dependent sodium channel blocker. It is currently the most advanced candidate in the Trigeminal Neuralgia pipeline and is being evaluated in Phase III clinical development. Phase II Therapy * Rimegepant: Biohaven Pharmaceuticals - A calcitonin gene-related peptide (CGRP) receptor antagonist currently being evaluated in Phase II development for Trigeminal Neuralgia, with clinical development initiated in June 2019. Further product details on additional pipeline candidates are provided in the full report. Trigeminal Neuralgia Therapeutic Assessment The report provides comprehensive therapeutic assessment of Trigeminal Neuralgia drugs across multiple development and product parameters. Clinical Trial Phases * Late-stage products (Phase III). * Mid-stage products (Phase II). * Early-stage products (Phase I). * Preclinical candidates. * Discovery-stage candidates. * Discontinued and inactive pipeline candidates. Route of Administration * Intravenous. * Subcutaneous. * Oral. * Intramuscular. Molecule Type * Monoclonal antibody. * Small molecule. * Peptide. Product Type * Mono. * Combination. * Mono/Combination. Trigeminal Neuralgia Pipeline Development Landscape The Trigeminal Neuralgia pipeline reflects ongoing innovation across clinical and preclinical development, with multiple companies advancing therapies targeting neuropathic pain through differentiated mechanisms of action. The pipeline spans early discovery through Phase III clinical development and includes both active and inactive candidates, providing insights into the evolving research landscape. Discover Which Companies and Pipeline Therapies Are Advancing Trigeminal Neuralgia Treatment @ Trigeminal Neuralgia Pipeline Insights Scope of the Trigeminal Neuralgia Pipeline Report * Geography Covered: Global. * Coverage: 10+ companies and 10+ pipeline drugs across clinical and nonclinical development stages. * Clinical Stages Covered: Phase III, Phase II, Phase I, preclinical, discovery, inactive, and discontinued products. * Therapeutic Assessment: Product type, clinical stage, route of administration, and molecule type. * Additional Coverage: Collaborations, acquisitions and mergers, licensing, designations, and other product-related development activities. About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides actionable market intelligence and strategic insights across the pharmaceutical, biotechnology, and healthcare industries. With expertise in epidemiology forecasting, competitive intelligence, and pipeline analysis, DelveInsight helps organizations make informed business decisions and stay ahead in an evolving healthcare landscape. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Mehul Malhotra Email: Send Email Phone: 09650213330 Address:A-1 NV 89107 City: delhi State: Indiana Country: United States Website: https://www.delveinsight.com/
Trigeminal Neuralgia Pipeline Outlook highlights 10+ Companies and 10+ emerging therapies across clinical development stages. September 29 Trigeminal Neuralgia is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock-like or stabbing pain in a region of the face, most frequently affecting the distribution of the second (maxillary) or third (mandibular) division of the trigeminal nerve, with the right side of the face affected more often than the left. (Albany, US) September 28, 2026 - DelveInsight's "Trigeminal Neuralgia - Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Trigeminal Neuralgia pipeline landscape, covering clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, as well as inactive pipeline products. Geographic Reference Three types of trigeminal neuralgia have been delineated: classical, secondary, and idiopathic, with bilateral trigeminal neuralgia rare and warranting concern about an underlying neurologic or non-neurologic disorder affecting the cranium. Incidence is higher among women than men and increases with age. Key Takeaways from the Trigeminal Neuralgia Pipeline Report * The Trigeminal Neuralgia pipeline includes 10+ key companies developing therapies, with 10+ products spanning Phase III, Phase II, Phase I, preclinical, and discovery stages, along with discontinued and inactive candidates. * Biogen has the most advanced Trigeminal Neuralgia drug candidate in the pipeline, with Vixotrigine (BIIB074) currently in Phase III development. * Vixotrigine is a centrally and peripherally acting small molecule that functions as a voltage- and use-dependent sodium channel blocker, being developed by Biogen for the treatment of Trigeminal Neuralgia. * Rimegepant, developed by Biohaven Pharmaceuticals, is a calcitonin gene-related peptide (CGRP) receptor antagonist in Phase II development for Trigeminal Neuralgia, with a trial initiated in June 2019. * The pipeline includes therapies across multiple stages of development, highlighting continued innovation in neuropathic pain treatment. * Emerging therapies are being developed through diverse mechanisms, including sodium channel blockers and CGRP receptor antagonists. Gain Strategic Insights into the Trigeminal Neuralgia Pipeline Landscape * Explore the complete Trigeminal Neuralgia Pipeline Outlook. * Analyze Phase III, Phase II, Phase I, preclinical, and discovery-stage assets. * Evaluate emerging companies and late-stage pipeline therapies. * Understand therapeutic assessment by product type, route of administration, and molecule type. * Track collaborations, licensing, acquisitions, and other pipeline development activities. Explore detailed pipeline insights and emerging therapies @ Trigeminal Neuralgia Pipeline Insight Report Trigeminal Neuralgia Disease Overview Pain can be triggered by routine acts, including brushing teeth, shaving, touching the face, eating or drinking, speaking, or a breeze on the face. Diagnosis is clinical, based on pain restricted to the territory of one or more divisions of the trigeminal nerve and sudden, intense, very short paroxysms. The anticonvulsant agents carbamazepine and oxcarbazepine have been considered first-choice treatments for control of paroxysmal pain, with gabapentin, pregabalin, and antidepressant agents tried as additional agents. Microvascular decompression is favored as the surgical procedure for cases not responding to medication. Trigeminal Neuralgia Emerging Drugs Analysis The Trigeminal Neuralgia pipeline features multiple emerging therapies targeting neuropathic pain through novel mechanisms and differentiated therapeutic approaches. Phase III Therapy Counseling Services * Vixotrigine (BIIB074): Biogen - A centrally and peripherally acting small molecule voltage- and use-dependent sodium channel blocker. It is currently the most advanced candidate in the Trigeminal Neuralgia pipeline and is being evaluated in Phase III clinical development. Phase II Therapy * Rimegepant: Biohaven Pharmaceuticals - A calcitonin gene-related peptide (CGRP) receptor antagonist currently being evaluated in Phase II development for Trigeminal Neuralgia, with clinical development initiated in June 2019. Further product details on additional pipeline candidates are provided in the full report. Trigeminal Neuralgia Therapeutic Assessment The report provides comprehensive therapeutic assessment of Trigeminal Neuralgia drugs across multiple development and product parameters. Clinical Trial Phases * Late-stage products (Phase III). * Mid-stage products (Phase II). * Early-stage products (Phase I). * Preclinical candidates. * Discovery-stage candidates. * Discontinued and inactive pipeline candidates. Route of Administration * Intravenous. * Subcutaneous. * Oral. * Intramuscular. Molecule Type * Monoclonal antibody. * Small molecule. * Peptide. Product Type * Mono. * Combination. * Mono/Combination. Trigeminal Neuralgia Pipeline Development Landscape The Trigeminal Neuralgia pipeline reflects ongoing innovation across clinical and preclinical development, with multiple companies advancing therapies targeting neuropathic pain through differentiated mechanisms of action. The pipeline spans early discovery through Phase III clinical development and includes both active and inactive candidates, providing insights into the evolving research landscape. Discover Which Companies and Pipeline Therapies Are Advancing Trigeminal Neuralgia Treatment @ Trigeminal Neuralgia Pipeline Insights Counseling Services Scope of the Trigeminal Neuralgia Pipeline Report * Geography Covered: Global. * Coverage: 10+ companies and 10+ pipeline drugs across clinical and nonclinical development stages. * Clinical Stages Covered: Phase III, Phase II, Phase I, preclinical, discovery, inactive, and discontinued products. * Therapeutic Assessment: Product type, clinical stage, route of administration, and molecule type. * Additional Coverage: Collaborations, acquisitions and mergers, licensing, designations, and other product-related development activities. About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides actionable market intelligence and strategic insights across the pharmaceutical, biotechnology, and healthcare industries. With expertise in epidemiology forecasting, competitive intelligence, and pipeline analysis, DelveInsight helps organizations make informed business decisions and stay ahead in an evolving healthcare landscape. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Mehul Malhotra Email: Send Email Phone: 09650213330 Address:A-1 NV 89107 City: delhi State: Indiana Country: United States Website: https://www.delveinsight.com/
Basecamp Research raises $140M to advance AI-designed therapeutics. Sep 23, 2026, 09:00 ET * Oversubscribed Series C led by S32 with backing from NVIDIA and others * Funding will advance a pipeline of EDEN-designed therapeutics, starting with in vivo cell therapy, and expand pharmaceutical partnerships * The company has demonstrated strong preclinical results across multiple modalities and disease areas LONDON and BOSTON, Sept. 23, 2026 /PRNewswire/ - Basecamp Research, a frontier AI company developing AI-designed medicines, today announced a $140M Series C financing to train a new generation of EDEN models and advance a pipeline of AI-designed therapeutics towards clinical development. Basecamp's ambition is to develop cures for diseases that remain incurable by designing medicines that reprogram the body to repair itself. The company combines frontier AI models trained on proprietary biological data with technology for writing DNA sequences into cells. "We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how," said Glen Gowers, co-founder and CEO of Basecamp Research. "AI-based approaches promise to change what's possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most." The oversubscribed round was led by S32, with participation from Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Additional investment comes from senior leaders from across pharma, biotech, and global industry, including André Hoffmann, Vice-Chairman of Roche, who said: "The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalised, AI-designed therapeutics represent the next transformation of that journey. Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate." Applying EDEN to develop new therapies Basecamp Research is applying EDEN, its biological foundation model, to in vivo cell therapy - reprogramming a patient's cells inside the body. Today's cell therapies are limited both in the complexity of what they can deliver and by a manufacturing process that costs hundreds of thousands of dollars per patient. By pairing EDEN's ability to design long and complex DNA sequences with large serine recombinases that can precisely integrate them into the genome, Basecamp's platform aims to underpin the future of cell therapies, making them more sophisticated, more customisable and simpler to administer. This has the potential to transform how we treat cancer, autoimmune disease, and more. The company has demonstrated strong preclinical results across multiple modalities and disease areas. To expand its pharmaceutical partnerships, Basecamp has appointed Richard Pearce, formerly of Biogen, as Chief Business Officer. Andy Conrad, General Partner at S32 and former CEO of Google's Verily, who joins the Board of Directors, said: "AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people's lives. Basecamp Research is building an important technology platform at the center of that opportunity." The AI and data powering Basecamp Research's therapies At the centre of Basecamp Research's AI platform is the Trillion Gene Atlas, the world's largest proprietary biological AI training dataset. Built with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics, the Atlas draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents. Trained on this data, the company's EDEN models recognise patterns across a huge breadth of previously unseen biology. Unlike AI systems developed for a single scientific task, EDEN models aim to deliver a universal understanding of how DNA works across all of life. This means that the models can generate potential therapeutic candidates directly from information about a disease, an approach already demonstrated through Basecamp's collaboration with Anthropic on Claude Science. The EDEN models' capabilities include designing cell and gene therapies, enzymes and peptides. About Basecamp Research Basecamp Research trains frontier AI models for therapeutic design. The EDEN models are trained on the Trillion Gene Atlas, the world's largest proprietary genomic dataset, collected through partnerships in more than 30 countries worldwide. Its pipeline of EDEN-designed therapeutics, beginning with in vivo cell therapy, is advancing towards clinical development. Basecamp Research is headquartered in London with offices and labs in Cambridge, MA. SOURCE Basecamp Research
Cambridge, Mass. – May 14, 2026 – Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen.
LEQEMBI(R) Pen (subcutaneous formulation of LEQEMBI(R) approved in Japan for the treatment of early Alzheimer's Disease. The first and only anti-amyloid treatment in Japan that enable at-home administration for Alzheimer's Disease, a progressive disease. TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that "LEQEMBI(R) Pen", the subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) has been approved in Japan as a new route of administration. LEQEMBI Pen is an autoinjector formulation that enables administration by a care partner or patient self-administration, with two pens (totaling 500 mg) administered once weekly. With this approval, LEQEMBI treatment now offers a new option of once-weekly SC administration at home*, in addition to intravenous (IV) administration every two weeks in a hospital setting. LEQEMBI Pen may reduce the time required for anti-amyloid therapy administration compared with IV infusions (approximate injection time of 15 seconds per injection). In addition, at-home administration may reduce the burden of clinic visits for patients and their care partners and provide greater flexibility in treatment, allowing patients to make treatment choices that better fit their lifestyles, including fewer constraints on going out and traveling. The improved convenience and flexibility of treatment with LEQEMBI is expected to lower barriers to initiating and continuing treatment with LEQEMBI. Furthermore, LEQEMBI Pen also has the potential to reduce healthcare resources associated with IV dosing, such as nurse monitoring, as well as maintaining infusion capacity. These features are expected to contribute to further streamlining the overall Alzheimer's disease (AD) treatment pathway. For amyloid-related imaging abnormalities (ARIA) monitoring, as with IV administration, brain magnetic resonance imaging (MRI) is performed prior to initiating treatment and at specified time points after treatment initiation. AD is a progressive, relentless disease with Aβ and tau as hallmarks that is caused by a continuous underlying neurotoxic process driven by protofibrils that begins before amyloid plaque accumulation and continues after plaque removal.[1,2,] [3] Only LEQEMBI fights AD in two ways - targeting both protofibrils and amyloid plaque. This marks the third country globally to approve LEQEMBI SC formulation. This approval is based on the integrated results of data and associated modeling and simulation from the 18-month core study of the Phase 3 Clarity AD study of LEQEMBI in patients with mild cognitive impairment (MCI) due to AD or mild AD dementia (collectively referred to as early AD), as well as multiple SC administration sub-studies in its subsequent long-term extension study (LTE). Once-weekly administration of SC formulation 500 mg demonstrated similar exposure to IV administration once every two weeks and supported the expectation that the SC formulation provides efficacy comparable to that of the IV formulation. The overall safety profile of SC administration was generally similar to that of IV administration, while systemic injection/infusion-related reactions were observed less frequently with SC administration (1.4%)** than with IV administration. Eisai serves as the lead for lecanemab's development and regulatory submissions globally, with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. * At-home, self-administration using LEQEMBI Pen will be possible after it is listed in the injectable drug list designated by the Minister of Health, Labour and Welfare that health insurance doctor can administer (or prescribe), following deliberation and approval by the Central Social Insurance Medical Council, in principle within 60 days after approval. In addition, the following points are stipulated to be observed when self-administering. * When initiating administration, treatment must be administered by a physician or under the direct supervision of a physician at a medical facility. * With regard to the applicability of self-administration, the appropriateness thereof shall be carefully considered, and only after providing thorough education and training, and confirming that the patient or family member/caregiver understands the risks associated with administration of this drug and how to respond to them, and that the patient or family member/caregiver is able to reliably administer it themselves, shall self-administration be implemented under the management and guidance of a physician. ** Incidence in participants newly initiated on lecanemab treatment via SC administration, based on clinical data obtained from once-weekly subcutaneous administration of lecanemab 720 mg using vial formulations. | Eisai Co., Ltd. Public Relations Department TEL: +81 (0)3-3817-5120 Eisai Europe, Ltd. EMEA Communications Department +44 (0) 7760 619251 [email protected] Eisai Inc. (U.S.) Libby Holman +1-201-753-1945 [email protected] | Biogen Inc. Madeleine Shin +1-781-464-3260 [email protected] | | INVESTOR CONTACTS | / | | Eisai Co., Ltd. Investor Relations Department TEL: +81 (0) 3-3817-5122 | Biogen Inc. Tim Power + 1-781-464-2442 [email protected] | | / | / | Notes to Editors References * Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z * Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. * Hampel H, Hardy J, Blennow K, et al. The amyloid pathway in Alzheimer's disease. Mol Psychiatry. 2021;26(10):5481-5503. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Healthcare Industry Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.